蛋白酶激活受体-4:准备成为抗血栓形成谱的一部分
Izabella Andrianova1, Mia Kowalczyk2, Frederik Denorme1
1Department of Emergency Medicine, Washington University School of Medicine, St. Louis, Missouri.
Current opinion in hematology
|May 30, 2024
概括
血小板受体PAR4 (蛋白酶激活受体-4) 在中风等心血管疾病中至关重要. 向PAR4提供了一个有前途的,安全的抗血栓策略,具有低出血风险.
科学领域:
- 心血管研究研究心血管研究
- 血栓形成和血液静止.
- 分子生物学分子生物学
背景情况:
- 心血管疾病是全球主要的死亡原因.
- 血小板是心血管病理学的关键参与者.
- 氨酸通过蛋白酶激活受体 (PAR1和PAR4) 调节血小板活性.
研究的目的:
- 审查有关血小板PAR4的文献.
- 专注于PAR4在血栓炎症中的作用.
- 探索PAR4作为抗血栓策略的治疗点.
主要方法:
- 对血小板PAR4研究的文献综述.
- 分析功能性PAR4变异及其与血栓形成和中风风险的关联.
- 对人性化小鼠模型的检查,以研究人体PAR4 in vivo.
主要成果:
- 功能性PAR4变异与静脉血栓和缺血性中风的风险变化有关.
- 人性化小鼠模型能够更好地理解人类与小鼠的PAR4差异.
- 这些模型有助于单核酸多态 (SNP) 和药物效应的体内测试.
结论:
- PAR4在心血管疾病中发挥重要作用,包括中风,心肌梗塞和动脉样硬化.
- 抑制PAR4是一种潜在的安全抗血栓治疗.
- 向PAR4可能为管理血栓性疾病提供一种新的方法.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
675
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
675
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
519
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
519
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
167
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
167
Receptor Tyrosine Kinases
12.7K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
12.7K


